BL
BMRN icon

Balentine LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Balentine LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,206
Closed -$228K – 609
2022
Q4 		$228K Sell
2,206
-212
-9% -$19.9K 0.01% 503
2022
Q3 		$205K Sell
2,418
-296
-11% -$26.4K 0.01% 483
2022
Q2 		$225K Buy
+2,714
New +$216K 0.01% 506
2020
Q3 		– Sell
-28
Closed -$3K – 237
2020
Q2 		$3K Sell
28
-248
-90% -$24.6K ﹤0.01% 786
2020
Q1 		$23K Buy
+276
New +$23.8K ﹤0.01% 254
2019
Q4 		– Sell
-37
Closed -$2K – 616
2019
Q3 		$2K Buy
+37
New +$2.85K ﹤0.01% 631
2018
Q1 		– Sell
-42
Closed -$4K – 120
2017
Q4 		$4K Sell
42
-45
-52% -$3.91K ﹤0.01% 531
2017
Q3 		$8K Hold
87
– – ﹤0.01% 482
2017
Q2 		$8K Hold
87
– – ﹤0.01% 459
2017
Q1 		$8K Buy
87
+42
+93% +$3.74K ﹤0.01% 432
2016
Q4 		$4K Buy
45
+10
+29% +$860 ﹤0.01% 455
2016
Q3 		$3K Hold
35
– – ﹤0.01% 421
2016
Q2 		$3K Hold
35
– – ﹤0.01% 414
2016
Q1 		$3K Hold
35
– – ﹤0.01% 308
2015
Q4 		$4K Buy
35
+8
+30% +$835 ﹤0.01% 390
2015
Q3 		$3K Buy
+27
New +$3.61K ﹤0.01% 432

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Balentine LLC's BMRN Position: Q1 2023 in Review

Balentine LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 2,206 shares — an estimated $228K sold.

Balentine LLC first reported a position in BMRN in Q3 2015 and held it in 16 quarters. The position peaked at $228K in Q4 2022. 551 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • Balentine LLC reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Balentine LLC sold 2,206 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $228K.
  • Balentine LLC first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 16 quarters.
  • Balentine LLC's BioMarin Pharmaceuticals position peaked at $228K in Q4 2022.
  • 551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Balentine LLC's 13F filing for Q1 2023, filed 11 May 2023.